A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

NCT03970382 · clinicaltrials.gov ↗

PHASE1

Phase

SUSPENDED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Solid Tumor

Interventions

BIOLOGICAL: NeoTCR-P1 adoptive cell therapy
BIOLOGICAL: nivolumab
BIOLOGICAL: IL-2

Sponsor

PACT Pharma, Inc.